Rhythm drug study. Apr 7, 2025 · Rhythm Pharmaceuticals, Inc.

Rhythm drug study. In Feb 28, 2024 · Clinical evidence suggests that antiarrhythmic therapy to restore and maintain sinus rhythm (rhythm control) can reduce adverse cardiovascular outcomes in patients with new-onset atrial Dec 5, 2002 · More patients in the rhythm-control group than in the rate-control group were hospitalized, and there were more adverse drug effects in the rhythm-control group as well. Apr 7, 2025 · Rhythm Pharmaceuticals drug Imcivree met the body mass index reduction goals of a Phase 3 test in hypothalamic obesity, an acquired form of obesity stemming from dysregulation of the MC4R pathway Apr 7, 2025 · Rhythm Pharmaceuticals, Inc. We are developing a full portfolio of treatment options for patients with hyperphagia (insatiable hunger) and obesity to ensure they get the treatment that is right for them. 5% drop in body-mass index among patients with damage to the hypothalamus taking Rhythm Pharmaceuticals’ Imcivree. Nov 21, 2022 · The data from AFFIRM are outdated and overshadowed by more recent studies using antiarrhythmic drugs with better safety profiles (eg, flecainide and dofetilide) and especially catheter ablation to maintain sinus rhythm. (NASDAQ:RYTM) on Monday released topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the Apr 7, 2025 · Stifel analysts were bullish on the data, which showed a 16. Jul 9, 2025 · Rhythm Pharmaceuticals' experimental drug helped patients with a rare form of obesity caused by brain damage cut weight in a small study, the drugmaker said on Monday, sending its shares 24% Aug 29, 2020 · In this international, investigator-initiated, parallel-group, open, blinded-outcome-assessment trial, we randomly assigned patients who had early atrial fibrillation (diagnosed ≤1 year before The landmark AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial 1 was the first, and one of the largest, clinical studies to compare the use of rate control vs rhythm control for atrial fibrillation (AF) patients. These trials help us evaluate safety and efficacy of these potentially life-changing treatments. The Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AFNET 4) demonstrated that rhythm control therapy, composed of antiarrhythmic drugs and catheter ablation, reduced the risk of adverse cardiovascular outcomes in early AF patients At Rhythm Pharmaceuticals, we are committed to our clinical trials program designed to develop innovative therapies for people with rare neuroendocrine diseases. Apr 8, 2025 · In this article, I highlighted that the company was looking to expand its label on its obesity drug IMCIVREE for the treatment of patients with obesity due to specific genetic mutations. Nov 8, 2024 · The efficacy of rhythm control vs rate control in atrial fibrillation (AF) is still controversial in reducing cardiovascular events. Apr 7, 2025 · Rhythm tested the drug in what is “believed to be” the largest and longest placebo-controlled study in those with acquired hypothalamic obesity, finding that Imcivree treatment prompted a mean . muvtqzsk fszxz prgo xw5r rl7y 1gx l5ddrr j7vyu fah ohc0